Zelys 1 Chewable Tablet 1.25mg

When a dog's heart struggles to pump blood effectively, it can lead to conditions like valvular insufficiency or dilated cardiomyopathy, commonly grouped under canine congestive heart failure. Zelys 1 Chewable Tablet 1.25mg works through its active ingredient, Pimobendan, which helps the heart pump more efficiently and improves blood flow throughout the body.

How Zelys 1 Chewable Tablet 1.25mg Works

Pimobendan, the active substance in Zelys 1 Chewable Tablet 1.25mg, operates via a dual mechanism:

• Increased Myocardial Contractility: It enhances the heart muscle's ability to contract, allowing it to pump blood more effectively.
• Vasodilation: It widens blood vessels, reducing the workload on the heart and improving overall circulation.

These actions combine to alleviate the strain on your dog's heart, helping to reduce symptoms such as fatigue, coughing, and breathing difficulties, thereby contributing to a better quality of life and potentially extending their lifespan. As a chewable tablet, Zelys 1 Chewable Tablet 1.25mg is designed to be palatable, making administration easier for pet owners.

Amounts to be administered and administration route:

• Do not exceed the recommended dosage.
• Determine the bodyweight accurately before treatment to ensure correct dosage.
• The tablets should be administered orally at a dose range of 0.2 mg to 0.6 mg pimobendan/kg body weight per day. The preferable daily dose is 0.5 mg pimobendan/kg body weight.
• The dose should be divided into two administrations (0.25 mg/kg body weight each), using a suitable combination of whole, or half of tablets.
• One half of the dose in the morning and the other half approximately 12 hours later.
• Each dose should be given approximately one hour before feeding.
• Spontaneous intake by the animal or place the tablet behind the lingual torus.
• For a body weight of 5 kg, this corresponds to one 1.25 mg chewable tablet in the morning and one 1.25 mg chewable tablet in the evening.
• Tablets are divisible in 2 for the 1.25 mg, 5 mg and 10 mg tablets.
• The product may be combined with a diuretic treatment such as furosemide.

Special precautions for use in animals:

• The blood glucose should be tested regularly during treatment in dogs with existing diabetes mellitus.
• Monitoring of cardiac function and morphology is recommended in animals treated with pimobendan.
• The chewable tablets are flavoured. To avoid any accidental ingestion, store tablets out of reach of the animals.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

• Accidental ingestion, especially by a child, may lead to tachycardia, orthostatic hypotension, flushing of the face and headaches.
• Unused part-tablets should be returned to the open blister space, or to the bottle and inserted back into the outer packaging. Keep in a safe place out of the sight and reach of children.
• Close bottle tightly with cap directly after removal of the required number of tablets or part-tablets.
• In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.
• Wash hands after use.

Adverse reactions (frequency and seriousness):

In rare cases, a slight positively chronotropic effect (rise in heart rate) and vomiting can occur. These effects are dose-dependent and can be avoided by reducing the dose.

In rare cases, transient diarrhoea, anorexia, or lethargy have been observed.

Although a relationship with pimobendan has not been clearly established, in very rare cases, signs of effects on primary haemostasis (petechiae on mucous membranes, subcutaneous haemorrhages) may be observed during treatment. These signs disappear when the treatment is withdrawn.

In rare cases, an increase in mitral valve regurgitation has been observed during chronic pimobendan treatment in dogs with mitral valve disease.

Use during pregnancy, lactation or lay:

Laboratory studies have shown evidence of maternotoxic and embryotoxic effects at high doses, and that pimobendan is excreted into milk. The safety of the product has not been assessed in pregnant or nursing bitches. Use only according to the benefit/risk assessment by the responsible veterinarian.

Interaction with other medicinal products and other forms of interaction:

No interaction between cardiac glycosides strophanthin and pimobendan was observed. The pimobendan-induced increase in cardiac contractility is attenuated by calcium antagonists (verapamil and diltiazem) and by the β-antagonist (propranolol).

Overdose (symptoms, emergency procedures, antidotes):

In case of overdose, a positive chronotropic effect, vomiting, apathy, ataxia, heart murmurs or hypotension may occur. In this situation, the dosage should be reduced and appropriate symptomatic treatment initiated. Prolonged exposure (6 months) of healthy beagle dogs at 3 and 5 times the recommended dose showed mitral valve thickening and left ventricular hypertrophy in some dogs.

Active substance:

• Pimobendan 1.25 mg

Excipients:

• Silica colloidal anhydrous
• Stearic acid
• Copovidone
• Croscarmellose sodium
• Malic acid
• Maize starch
• Cellulose microcrystalline
• Lactose monohydrate
• Dried Yeast (from Saccharomyces cerevisiae)
• Pig liver powder